Jeevan Sekhar, MD
Hematology & Oncology · Columbus, OHNPI 1598802852
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $327 and has fallen 90.3% since, to $32 in 2022. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 29 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$95
- E.r. Squibb & Sons, L.L.C.$54
- Pfizer$45
- Puma Biotechnology, Inc.$28
- Tersera Therapeutics LLC$27
- Merck$26
- plus $192 from 12 others
What the payments were for
- Food & beverage$43593%
- Education$327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Pfizer | 2 | $45 |
| Puma Biotechnology, Inc. | 2 | $28 |
| Tersera Therapeutics LLC | 2 | $27 |
| Merck | 2 | $26 |
| Incyte Corporation | 1 | $23 |
| Bayer | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Exelixis Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Gilead | 1 | $14 |
| GSK | 1 | $13 |
| Novartis | 1 | $12 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
How this compares
$467 in reported general payments places this provider in the 25th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 14 | $230 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.